Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzo Biochem has announced the acquisition of substantially all of the US based assets of Biomol International, and all of the stock of its two-wholly-owned UK subsidiaries.
Subscribe to our email newsletter
With this acquisition, Enzo Life Sciences now has US operations in New York, Pennsylvania and California, and overseas facilities in Switzerland, the UK and Belgium, as well as more than 50 distributors worldwide.
The purchase price of $18 million is comprised of $15 million in cash and $3 million in unregistered stock, in addition to earn-outs over the next two years. Biomol’s founders and senior management will remain actively involved with Enzo Life Sciences.
Barry Weiner, Enzo’s president, said: “Coupling Biomol with our acquisition of Axxora Life Sciences less than a year ago, we have succeeded in transforming Enzo Life Sciences into a global manufacturer and marketer of reagents and systems spanning a wide spectrum of scientific applications.”